Julie A Tucker

List of Publications by Year
in descending order

44 papers	2,529 citations	201674 27 h-index	254184 43 g-index
44 all docs	44 docs citations	44 times ranked	3923 citing authors

#	Article	IF	Citations
1	Purification of a rat neurotensin receptor expressed in Escherichia coli. Biochemical Journal, 1996, 317, 891-899.	3.7	200
2	Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Structural Biology, 2002, 9, 745-749.	9.7	198
3	Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation. Journal of Medicinal Chemistry, 2012, 55, 3285-3306.	6.4	144
4	Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3Î² (GSK3Î²) Inhibitors for Alzheimerâ€™s Disease: Design, Synthesis, and Characterization of Pyrazines. Journal of Medicinal Chemistry, 2012, 55, 9107-9119.	6.4	126
5	Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations. Science, 2020, 367, 643-652.	12.6	123
6	Cyclin-dependent kinases: inhibition and substrate recognition. Current Opinion in Structural Biology, 1999, 9, 738-744.	5.7	109
7	Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation. Journal of Medicinal Chemistry, 2015, 58, 2265-2274.	6.4	104
8	First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib. ACS Chemical Biology, 2016, 11, 3179-3190.	3.4	101
9	Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-Bis anilino pyrimidines. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2955-2960.	2.2	94
10	Probing the ATP Ribose-Binding Domain of Cyclin-Dependent Kinases 1 and 2 withO6-Substituted Guanine Derivatives. Journal of Medicinal Chemistry, 2002, 45, 3381-3393.	6.4	90
11	How Tyrosine 15 Phosphorylation Inhibits the Activity of Cyclin-dependent Kinase 2-Cyclin A. Journal of Biological Chemistry, 2007, 282, 3173-3181.	3.4	85
12	Crystal Structure of Human Thymidine Phosphorylase in Complex with a Small Molecule Inhibitor. Structure, 2004, 12, 75-84.	3.3	82
13	Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4. Structure, 2014, 22, 1764-1774.	3.3	81
14	Imidazo[1,2- b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2249-2252.	2.2	78
15	Aminopyrazinamides: Novel and Specific GyrB Inhibitors that Kill Replicating and Nonreplicating Mycobacterium tuberculosis. ACS Chemical Biology, 2013, 8, 519-523.	3.4	76
16	Structure-based design of protein tyrosine phosphatase-1B inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2503-2507.	2.2	68
17	Quantitative Evaluation of Neurotensin Receptor Purification by Immobilized Metal Affinity Chromatography. Protein Expression and Purification, 1997, 11, 53-60.	1.3	66
18	Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2961-2966.	2.2	61

#	Article	IF	Citations
19	Thiazolopyridine Ureas as Novel Antitubercular Agents Acting through Inhibition of DNA Gyrase B. Journal of Medicinal Chemistry, 2013, 56, 8834-8848.	6.4	55
20	Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase. Nature Communications, 2015, 6, 7877.	12.8	52
21	Structures of the Human Poly (ADP-Ribose) Glycohydrolase Catalytic Domain Confirm Catalytic Mechanism and Explain Inhibition by ADP-HPD Derivatives. PLoS ONE, 2012, 7, e50889.	2.5	46
22	Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKÎµ kinases. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2063-2069.	2.2	42
23	The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6369-6373.	2.2	41
24	Structure Guided Lead Generation for M. tuberculosis Thymidylate Kinase (Mtb TMK): Discovery of 3-Cyanopyridone and 1,6-Naphthyridin-2-one as Potent Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 753-766.	6.4	40
25	Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4442-4446.	2.2	32
26	Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6670-6674.	2.2	32
27	Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. Nature Communications, 2020, 11, 1383.	12.8	30
28	Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5487-5492.	2.2	28
29	Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH). Oncotarget, 2017, 8, 104478-104491.	1.8	27
30	Title is missing!. Biotechnology Letters, 1997, 19, 425-428.	2.2	26
31	Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. Oncotarget, 2018, 9, 13139-13153.	1.8	25
32	Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides. Journal of Medicinal Chemistry, 2018, 61, 10767-10792.	6.4	23
33	The thrombopoietin receptor: revisiting the master regulator of platelet production. Platelets, 2021, 32, 770-778.	2.3	23
34	Small molecule ERK5 kinase inhibitors paradoxically activate ERK5 signalling: be careful what you wish forâ€¦. Biochemical Society Transactions, 2020, 48, 1859-1875.	3.4	22
35	Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9. MedChemComm, 2016, 7, 1580-1586.	3.4	19
36	Keep it together: restraints in crystallographic refinement of macromoleculeâ€“ligand complexes. Acta Crystallographica Section D: Structural Biology, 2017, 73, 93-102.	2.3	19

#	Article	IF	Citations
37	Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site. Acta Crystallographica Section D: Structural Biology, 2016, 72, 682-693.	2.3	15
38	Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38Î± and BRD4. European Journal of Medicinal Chemistry, 2019, 178, 530-543.	5.5	15
39	FGFR1 Kinase Inhibitors: Close Regioisomers Adopt Divergent Binding Modes and Display Distinct Biophysical Signatures. ACS Medicinal Chemistry Letters, 2014, 5, 166-171.	2.8	14
40	An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-ÎºB-Inducing Kinase. Journal of Medicinal Chemistry, 2021, 64, 10001-10018.	6.4	9
41	Validation of ion mobility spectrometry â€•mass spectrometry as a screening tool to identify type II kinase inhibitors of FGFR1 kinase. Rapid Communications in Mass Spectrometry, 2021, , e9130.	1.5	4
42	Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 6513-6540.	6.4	3
43	Recent Advances in Kinase Drug Discovery Part I: The Editorsâ€™ Take. International Journal of Molecular Sciences, 2021, 22, 7560.	4.1	1
44	New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2V617F Mutation. Blood, 2019, 134, 2962-2962.	1.4	0